Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62,129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PRSS contributes to cetuximab resistance in colorectal cancer.
Tan Z, Gao L, Wang Y, Yin H, Xi Y, Wu X, Shao Y, Qiu W, Du P, Shen W, Fu L, Jia R, Zhao C, Zhang Y, Zhao Z, Sun Z, Chen H, Hu X, Xu J, Wang Y. Tan Z, et al. Among authors: xu j. Sci Adv. 2020 Jan 1;6(1):eaax5576. doi: 10.1126/sciadv.aax5576. eCollection 2020 Jan. Sci Adv. 2020. PMID: 31911942 Free PMC article.
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q. Xu J, et al. Clin Cancer Res. 2019 Jan 15;25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484. Epub 2018 Oct 22. Clin Cancer Res. 2019. PMID: 30348638 Clinical Trial.
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
Xu J, Li J, Bai C, Xu N, Zhou Z, Li Z, Zhou C, Jia R, Lu M, Cheng Y, Mao C, Wang W, Cheng K, Su C, Hua Y, Qi C, Li J, Wang W, Li K, Sun Q, Ren Y, Su W. Xu J, et al. Among authors: xu n. Clin Cancer Res. 2019 Jun 15;25(12):3486-3494. doi: 10.1158/1078-0432.CCR-18-2994. Epub 2019 Mar 4. Clin Cancer Res. 2019. PMID: 30833272 Clinical Trial.
Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J, Zhao X. Sun B, et al. Among authors: xu j. Cancer Immunol Res. 2019 Nov;7(11):1813-1823. doi: 10.1158/2326-6066.CIR-19-0026. Epub 2019 Sep 4. Cancer Immunol Res. 2019. PMID: 31484657
62,129 results
You have reached the last available page of results. Please see the User Guide for more information.